
    
      -  Prospective, randomized, single-blinded, multi-center clinical investigation comparing
           target vessel and non-intervened, self-control vessel within participants and between
           participants undergoing BVS or mDES deployment for the treatment of a single de novo
           native coronary artery lesion

        -  The investigation will include two arms:

             -  Study device (BVS) arm: Abbott Vascular's Everolimus-Eluting Bioresorbable Vascular
                Scaffold

             -  Control device (mDES) arm: Abbott Vascular's Everolimus-Eluting XIENCE V or XIENCE
                PRIME
    
  